A Phase 3, Open-Label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3).
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2011
At a glance
- Drugs Aztreonam (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AIR-CF3
- Sponsors Corus Pharma; Gilead Sciences
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 May 2008 6-month results reported at ATS 2008
- 15 Jun 2007 Status changed from recruiting to in progress.